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Abstract
Background: Alternative splicing is known to increase the complexity of mammalian transcriptomes since nearly all 
mammalian genes express multiple pre-mRNA isoforms. However, our knowledge of the extent and function of 
alternative splicing in early embryonic development is based mainly on a few isolated examples. High throughput 
technologies now allow us to study genome-wide alternative splicing during mouse development.
Results: A genome-wide analysis of alternative isoform expression in embryonic day 8.5, 9.5 and 11.5 mouse embryos 
and placenta was carried out using a splicing-sensitive exon microarray. We show that alternative splicing and isoform 
expression is frequent across developmental stages and tissues, and is comparable in frequency to the variation in 
whole-transcript expression. The genes that are alternatively spliced across our samples are disproportionately 
involved in important developmental processes. Finally, we find that a number of RNA binding proteins, including 
putative splicing factors, are differentially expressed and spliced across our samples suggesting that such proteins may 
be involved in regulating tissue and temporal variation in isoform expression. Using an example of a well characterized 
splicing factor, Fox2, we demonstrate that changes in Fox2 expression levels can be used to predict changes in 
inclusion levels of alternative exons that are flanked by Fox2 binding sites.
Conclusions: We propose that alternative splicing is an important developmental regulatory mechanism. We further 
propose that gene expression should routinely be monitored at both the whole transcript and the isoform level in 
developmental studies
Background
Developmental processes require precise spatial and tem-
poral regulation of gene expression. Accordingly, devel-
opmental biologists have always been at the forefront of
gene expression analysis, and recombinant DNA tech-
niques such as transgenic and knockout models have
greatly contributed to elucidation of developmental path-
ways and networks. Traditionally, these studies have
focused on transcription factors and repressors that regu-
late the timing and strength of transcription. Recently,
new regulatory mechanisms have emerged, such as post-
transcriptional regulation by microRNAs and co-tran-
scriptional regulation by alternative pre-mRNA splicing.
Alternative splicing is a pre-mRNA maturation process
that consists of the removal or inclusion of certain alter-
native exons to produce different transcripts from one
genomic locus [1,2]. Alternative splicing is now known to
be prevalent in advanced eukaryotes. In humans, recent
reports show that more than 98% of multi-exonic pre-
mRNAs are alternatively spliced [3,4]. The mouse
genome has been sequenced and, similarly to that of
humans, a surprisingly low number of less than 30,000
g e n e s  h a v e  b e e n  i d e n t i f i e d  [ 5 , 6 ] .  I t  h a s  b e e n  w i d e l y
hypothesized that the great complexity of higher eukary-
otic organisms stems from processes such as alternative
splicing [7,8]. The distinct proteins translated from iden-
tical pre-mRNAs produced by this process can have dif-
ferent, even antagonistic activities. Thus, alternative
splicing can play a major role in the activity of various
important cellular mechanisms, such as cell differentia-
tion, cell migration, cell growth and apoptosis. This wide
range of cellular processes is required during mammalian
embryogenesis to generate a viable organism from a sin-
gle cell.
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Several studies have suggested the importance of alter-
native splicing during development. In C. elegans, it was
shown that 18% of the 352 verified alternative exons
showed a larger than fourfold change in alternative splic-
ing during its development from embryo to adult, includ-
ing larval stages [9]. In humans, mice, chickens and
Xenopus, a well-known example is provided by the fibro-
blast growth factor 8 (FGF8), which can produce many
different isoforms [10]. Two of these, FGF8A and FGF8B,
which differ by only eleven amino acids, have been shown
to have different activities during development [11-14].
I t  has r ec e n t l y bee n s hown t ha t  t he  l ev e ls  of  c e rta in
splicing factors, MBNL and CELF, are regulated and vary
several-fold during pre- and postnatal heart development
[15]. This variation in CELF and MBNL expression levels
affects the splicing modulation of a large quantity of other
alternative splicing events, suggesting the existence of a
regulatory cascade at the splicing level. Some of the most
interesting examples of alternative splicing and its regula-
tion by splicing factors have been carried out in neural
tissues. As neuronal precursor cells differentiate into
neurons, there is a switch from the ubiquitous PTB to the
highly similar, but neuron-specific, neural PTB (nPTB)
[16]. As these two proteins modulate alternative splicing
of specific subsets of pre-mRNAs, there is an associated
switch of a large number of mRNA isoforms.
Since splicing factors may regulate alternative splicing
of many different pre-mRNAs [17,18], knocking out
known splicing factors in mice generally has profound
effects on embryo or young pup viability. The majority of
germ-line loss of function mutations in splicing factors
result in embryonic arrest early in development, before
embryonic day (E) 7.5, e.g. Ptb [19], SC35 [20,21], Asf2/
Sf2 [22] and SRp20 [23]. In two cases, Ptb and SRp20,
homozygous mutant embryos arrest at the morula stage
[19,23].  Prfp3  mutant embryos also exhibit embryonic
arrest, although it is not clear if these embryos die early
or late in embryogenesis [24]. Germ-line loss of function
mutations in splicing factors are also associated with
organ specific abnormalities. For example, most SRp38
knockout embryos die before E15.5 with multiple cardiac
defects [25], whereas a small number of mutant mice are
born only to die soon after birth [22]. Mbnl1 and Mbnl2
are required in the skeletal muscle and eye [26,27], and
Nova1 is required in motor neurons [20]. These studies
indicate that there are stage-specific and tissue-specific
requirements for splicing factors.
Although there have been a number of indications of
the importance of alternative splicing in development,
past studies have been limited largely to individual exper-
iments focused on known candidate genes. In recent
years, technological advances have paved the way to
genome-wide analyses of mRNA processing, and have
enabled hypothesis-free approaches. In this study, we
take advantage of a splicing-sensitive exon microarray to
investigate genome-wide variation in alternative splicing
during development of the mouse embryo and its associ-
ated placenta. We focus on early developmental stages,
E8.5-E11.5, in order to capture the isoform differences
occurring during organogenesis. In mouse embryos,
organogenesis begins at E8.5 and is mostly completed by
E11.5 when most organs of the foetus can be recognized.
The placenta is one of the first organs to form and func-
tion in the developing foetus. During organogenesis the
precursors of the adult organs undergo a series of mor-
phogenetic movements and differentiation events which
have been shown to be controlled by changes in gene
expression. We postulate that alternative splicing pro-
vides an additional mechanism for increasing the reper-
toire of transcripts from a limited number of
developmentally relevant genes and confers additional
specificity to individual developing tissues. Our results
show that alternative splicing is frequent during organo-
genesis, and that different tissues (i.e. the placenta and
embryo) as well as different developmental stages express
specific gene isoforms. We confirm some previously
described splicing events but also report numerous new
time- and tissue-specific alternative isoforms. In addi-
tion, we find that the mRNA expression levels of some
known splicing factors are modulated during organogen-
esis, suggesting that changes in expression levels of splic-
ing factors may be responsible for alternative isoform
expression.
Results
We studied the variation in gene expression at the tran-
script isoform level in two "tissues" - embryonic and pla-
centa - across three developmental stages: E8.5, E9.5, and
E11.5. Unfortunately, we were not able to obtain suffi-
cient amount of RNA from the chorion, the precursor of
the placental tissue, at E8.5 and had to omit that sample
from the analysis. For the remaining samples, 5 biological
replicates were obtained for each tissue/stage, and the
RNA from each replicate was hybridized to one Affyme-
trix GeneChip® Mouse Exon 1.0 ST microarray. This array
contains probes targeted to individual known and pre-
dicted exons, and allows monitoring of expression level at
a sub-exon resolution. The replicate nature of the data
allowed us to carry out analyses of variance (ANOVA) to
detect differences in expression levels across time points
and tissues. To investigate variations at the whole-tran-
script level, we performed the analysis using the summa-
rized expression estimates of entire transcripts. For
detection of differences in splicing and isoform expres-
sion, the expression levels of each individual probe set
(roughly corresponding to an exon) were normalized by
dividing by the expression level of the corresponding
gene. The latter method will be referred to as the splicingRevil et al. BMC Genomics 2010, 11:399
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index analysis. These two approaches allowed us to dif-
ferentiate the cases where all, or most of the exons, within
a gene have variable expression levels from the cases
where only some of the exons within a transcript behave
differently from the remaining exons, indicating alterna-
tive splicing or related isoform changes. This also allowed
us to detect changes such as alternative transcription
start sites or alternative polyadenylation sites which can
also affect the N- or C-terminus of proteins (Figure 1).
Data quality control and filtering
As the first quality control check, we carried out principal
component analysis (PCA) to estimate the sources of
variability within the data. PCA results from the whole-
transcript analysis are shown in Figure 2, but similar
trends are observed in exon-level, and normalized (Splic-
ing Index) data. The first two principal components
explain 48% of the variance of the data, and correspond to
the tissue effect (32.9%) and stage effect (15.1%). Individ-
ual samples form distinct clusters, illustrating clear differ-
ences in gene expression levels across the two tissues and
three stages.
We next carried out the splicing index analysis which
identified a large number of candidate exons predicted to
be alternatively spliced across the two tissues and three
stages. Since it is instrumental to distinguish between
truly alternatively spliced exons, and exons expressed at
very low levels (indistinguishable from background noise)
or very highly (beyond the sensitivity levels of the
microarray); we employed a number of filtering steps, as
described in Materials and Methods and previously in
[28]. The Affymetrix Mouse Exon Array contains over
23,000 core meta probe sets (genes) and 280,000 probe
sets (exons). Our filtering criteria reduced this number to
13,366 meta probe sets containing approximately 133,000
probe sets.
We investigated the efficacy of our data filtering steps
by estimating the percentage overlap between candidate
alternatively spliced exons in our study, with those pre-
dicted to be alternatively spliced based on independent
EST and mRNA evidence such as those annotated by the
"AltEvents" track from build 37 of the mouse genome on
the UCSC Genome browser [5,29,30]. The Alt-Events
track annotates alternative splice forms in UCSC "known"
genes, which are assembled by combining evidence from
multiple independent experimental sources. Application
of our data filtering steps increases the percentage over-
lap with alternative events predicted from independent
sources (Additional File 1 Figure S1). In addition, by
increasing the stringency of the false discovery rate (FDR)
cutoff we further increased the percentage overlap. This
analysis demonstrates that the application of data filter-
ing as well as the use of a stringent q-value cutoff
increases the agreement between our results and alterna-
tively spliced events predicted from independent experi-
mental evidence. We note, however, that while our data
filtering likely increases the sensitivity of our analysis, it is
likely that the filters concurrently reduce specificity.
Figure 1 Examples of types of alternative splicing analysed. The boxes represent exons while the lines are introns. The bold lines beneath the 
exons indicate probes that detected significant expression changes for each example and the arrows represent primers used for qRT-PCR analyses. 
(a) Alternative promoter use can be found by an increase in the expression detection levels for a probe set for one promoter compared to the others. 
The change in promoter use of Elmo1 alters the 5' untranslated region (white boxes) as well as the N-terminus of the protein. (b) The same analyses 
can be applied for alternative polyadenylation sites, in this case Kif1b. (c) Alternative exons can be included or excluded in the mature mRNA, thus 
altering the coding sequence as in the Kif2a pre-mRNA.
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Comparison of differentially expressed and spliced genes
To assess patterns of gene expression and splicing change
over our entire data set, we defined a significant differ-
ence as a P-value which was less than that expected at an
FDR of 0.05. Significant stage effects were defined using
the combined P-values from the embryo and placenta:
that is, a significant developmental stage effect reflects a
difference in expression between different embryonic
stages, placental stages or both. For brevity, we refer to
differences in expression between embryo and placenta
as "tissue-specific" and differences in expression between
developmental stages as "stage-specific".
We first examined differences in expression between
tissue and developmental stage at the level of whole gene
expression. We find that approximately equal numbers of
the 13,366 genes in our data set show a significant change
in expression between day of development (8,661) as
between placenta and embryo (8,475), with a large over-
lap between the two (5,857) (Figure 3A).
We next examined stage and tissue differences in inclu-
sion levels of individual exons. Of the nearly 300,000 core
probe sets, 133,758 remained expressed at detectable lev-
els after our filtering criteria. These probe sets are located
in a total of 10,796 genes. We find that, at a FDR of 0.05,
12,011 (9%) probe sets are differentially included in their
respective transcripts between embryo and placenta,
while 2,830 (2%) are differentially included between day
of development in either placenta or embryo, or both
(Figure 3B). We also find numerous examples (924) where
an exon is both tissue and stage-specific. For example, we
observe an increase in the use of the middle promoter of
Gcnt2  during embryo development, which in turn is
higher than its use in placentas (Figure 4B). This seems to
be due to changes in promoter use between tissues and
stages (Figure 4C). Our results suggest that at least one
putatively alternatively spliced exon is found in a total of
5,549 genes. A substantial fraction (21%) of these genes
contains both a tissue-specific and stage-specific alterna-
tively spliced exon (Figure 3C). In a majority of cases (824
genes), this is due to the alternative splicing of the same
exon in a tissue and stage-specific manner.
We next investigated the overlap between whole gene
expression change and alternative splicing. For clarity, in
this section we focused on the 10,796 genes which con-
tained at least one filtered (clearly expressed) probe set.
We find that genes whose expression is significantly dif-
ferent between tissues or stages are highly enriched for
alternatively spliced exons (Figure 3D). Genes that are
differentially expressed between tissue are primarily
enriched (compared to all genes) in tissue-specific alter-
native exons, while genes that are differentially expressed
between developmental stages are likewise enriched in
stage-specific alternative exons (Figure 3D). This analysis
suggests that a large proportion of genes that are differen-
tially expressed in early embryonic development concur-
rently exhibit significant isoform changes.
Developmental processes and functions are 
overrepresented in alternatively spliced genes
To identify alternative isoforms in genes with a role in
mammalian development, we used the simplified PAN-
THER gene ontology [31]. We tested for functional anno-
tations that were enriched in the 1,828 genes with one or
more developmentally-regulated alternative isoforms,
compared to the expected distribution of annotation
terms derived from a reference gene set. In our case, the
reference set was comprised of all genes which we
detected as expressed in the embryonic and placental
samples. The results of this analysis (Tables 1 and 2) sug-
gest that our candidate genes are active in important
aspects of mammalian development. In particular, our
candidate alternatively spliced genes appear to be active
in cell attachment to the extracellular matrix, an integral
process during organogenesis [32].
Classification and visualization of alternative isoforms
In order to classify, visualize, and evaluate the candidate
alternative isoforms predicted by statistical analysis of
exon microarray data, we created a database that links the
Figure 2 Principal component analysis. PCA was performed on the 
whole transcript levels. The plot shows that there is consistent behav-
iour (clustering) across biological replicates of the same samples. The 
two major sources of variation in the data are the tissue effect, which 
approximately corresponds to the 1st principal component (horizontal 
axis), and the stage effect (vertical axis).Revil et al. BMC Genomics 2010, 11:399
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results to the UCSC Genome Browser [29] and allows
evaluation of each isoform in the context of all other
available information, such as gene structure, expression
information, as well as all other functional data provided
by UCSC. The results are available in the additional data
online (Additional file 2 Table S1). Figure 5 provides a
concrete example of how microarray data and gene struc-
ture information can be combined to infer mutually
exclusive alternative splicing of two neighbouring exons
in the gene Rab6.
Microarray results are confirmed by RT-PCR and qRT-PCR
The first level of validation of the microarray results was
performed using end-point RT-PCR analysis. To simplify
primer design and subsequent analysis, only alternative
splicing events implicating cassette exons were verified
using primers encompassing the alternative exons. Ten
randomly chosen candidates with probe sets that over-
lapped at least partially with an existing cDNA, mRNA or
EST-supported alternative exon, were selected (Table 3).
All the ten exons verified were alternatively spliced in at
least one of the sampled tissues (Additional file 3 Figure
S2), and, in the cases where it could be quantified from
the brightness of the corresponding bands in the gel, the
trends of exon inclusion levels were in agreement with
the microarray analysis.
To further verify the precise quantitative patterns of
exon inclusion of the genes where the end-point quantifi-
cation was not conclusive, we selected five of the already
confirmed alternative cassette exons for analysis using
quantitative real-time PCR. We also analysed seven addi-
tional alternative isoform events: four alternative pro-
moters, two alternative polyadenylation sites, and one
case of mutually exclusive exons (Table 4). We compared
fold changes of the average of values for the qRT-PCR on
the candidate exons with microarray probe set inclusion
levels (see examples in Figure 6, compare blue lines with
red bar graphs, respectively). The qRT-PCR based
expression levels of all of these alternative splicing events
displayed the same quantitative trend as earlier observed
in the microarray analysis.
In order to gain further insight into temporal variation
in isoform expression, the qRT-PCR was performed on
additional embryonic and placental stages, ranging from
Figure 3 Distribution of differentially expressed or spliced candidates. (a) Number of genes that show significant expression changes between 
placental and embryonic tissues and between development stages, as well as the overlap between the two sets. (b) Individual probe sets that are 
differentially expressed compared to their transcripts between tissues and between stages. (c) Number of genes that contain at least one alternatively 
spliced exon when comparing embryo or placentas, or between developmental days. (d) Comparison of the percentage of tissue- or stage-depen-
dent differentially alternatively spliced genes, or either, in three different subsets of differentially expressed genes: all, tissue-specific or stage-specific.
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E 6  t o  E 1 1 .  T h e  r e s u l t s  o f  t h e s e  a d d i t i o n a l  s t a g e s  w e r e
almost all predictable by extrapolation of the trends
observed in the microarrays. A few demonstrated some
unexpected behaviour, which may correspond to rapid
changes in splicing patterns corresponding to develop-
mental switches. As mice embryos develop extremely
rapidly, with a gestation period of only 19-21 days, it is
possible that the alternative splicing of certain pre-
mRNAs can also be modified extremely rapidly.
The seventeen validated candidates are implicated in
various cellular and organismal processes, and some have
previously been shown to be involved in embryogenesis.
For example, Numb is involved in neuronal differentia-
tion during development. There are four known isoforms
Figure 4 Gcnt2 promoter use during embryogenesis. (a) Expression of the Gcnt2 gene is driven by three promoters, each contributing to different 
N-termini for the protein. (b) The use of the middle promoter is generally higher in the embryo than the placenta as detected by the probe set (PS) 
4867798, and its use increases during development. (c) Comparison of the use of each three promoters, normalized to gene expression levels, shows 
a distinct profile for each promoter when comparing developmental stages and tissues.
Distal prom.
(PS: 5481529)
Middle prom.
(PS: 4867798)
Proximal prom.
(PS: 5481529)
E8.5 E9.5 E11.5 P9.5 P11.5
B
A
C Middle promoter
PS: 4867798
1
0
-1
-2
-3
N
o
r
m
a
l
i
z
e
d
 
e
x
p
r
e
s
s
i
o
n
 
(
l
o
g
2
)
E8.5 E9.5 E11.5 P9.5 P11.5
100%
75%
50%
25%
0%
Middle promoter
Proximal promoter
Distal promoter
Table 1: Overrepresented PANTHER "Biological Process" terms.
PANTHER Biological Process Observed Expected P-value
Cell adhesion 70 37.61 3.24 e-05
Developmental processes 218 160.69 8.49 e-05
Signal transduction 291 234.45 1.59 e-03
Cell adhesion-mediated signaling 43 21.22 3.61 e-03
Ectoderm development 80 50.05 6.14 e-03
Transport 130 94.69 6.45 e-03
Neurogenesis 70 44.34 3.52 e-02Revil et al. BMC Genomics 2010, 11:399
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of Numb, two of which contain an alternative exon of 147
nt in the proline rich region and two without this exon
[33]. These two classes have been shown to be differen-
tially spliced during embryogenesis from E10 to E17, as
well as in adults, to regulate cortical development [34].
This shift in alternative splicing is confirmed by our
microarray results and we also find that this starts as
soon as E8.5, the earliest data we have for this alternative
splicing event.
Multiple RNA-binding proteins are alternatively expressed 
and spliced during development
We examined our data set for differential expression and
splicing of RNA-binding genes, since RNA-binding pro-
teins (RBPs) may be involved in regulating tissue and
Table 2: Overrepresented PANTHER "Molecular Function" terms.
PANTHER Molecular Function Observed Expected P-value
Extracellular matrix structural protein 23 6.44 4.96 e-05
Cell adhesion molecule 44 23.42 2.36 e-03
Extracellular matrix 44 23.86 3.53 e-03
Figure 5 Alternative splicing of Rab6. This pre-mRNA contains two mutually exclusive alternative exons, exons 4 and 5 (see middle panel represent-
ing the Rab6 gene structure using the UCSC Genome browser [29], http://genome.ucsc.edu). The top panel shows raw expression scores for each 
probe set for the three embryonic developmental stages. There is a slight difference in the expression of the entire transcript, as most probe sets in-
crease their intensities from embryonic day (E) 8.5 to E11.5. This trend is not consistent for exons 4 and 5, as the inclusion of exon 4 actually goes down 
while the inclusion of exon 5 increases disproportionally. This is further emphasized in the bottom panel, showing the splicing index analysis and the 
expression values of each exon normalized to adjust for whole transcript expression changes. On the right, the bar graph shows the actual (log2 scale) 
reduction of exon 4 inclusion across the 3 day time span.
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temporal variation in isoform expression. Using a list of
380 putative RBPs recently published [35] as well as oth-
ers added subsequently, we found that many RBPs are dif-
ferentially expressed between the two tissues and three
stages (Table 5). One interesting candidate is the alterna-
tive splicing factor CELF/BRUNOL4, which we observe
to be regulated at both the expression and splicing levels.
The global expression of this gene increases more than
2.5-fold in the embryo between E9.5 and E11.5. Mean-
while, in the same tissue samples and stages, the inclusion
of exon 8 increases ten-fold and the use of a differential 3'
end exon goes up 3.5 fold while in the placenta use of this
3' end exon goes down 4.5 fold between E9.5 and E11.5
(Additional file 2 Table S1). Although the consequence of
this change of gene expression or alternative splicing is
unknown, levels of CELF4/BRUNOL4 proteins are regu-
lated during development of the brain and skeletal mus-
cles between E14, newborn, postnatal day 4 and adult
mice [36].
Another particularly interesting candidate is Rbm9,
also known as Fox-2. This protein is implicated in the reg-
ulation of alternative splicing in neurons and muscles [37]
and has been shown as important for the survival of
human embryonic stem cells [38]. According to our
results, during embryogenesis, the expression levels of
the isoforms in embryos nearly double from E8.5 to E11.5
(Figure 7B). Furthermore, the alternative splicing of the
Fox-2 pre-mRNAs is significantly modified, with increas-
ing use of the proximal promoter during development of
both embryos and placentas, compared to E8.5 (Figure
7C). This leads to a different 5'UTR but also to a shorter
N-terminal on the resulting protein. The effect of this
switch of promoters is currently unknown but may play a
role on the activity of this protein. Other exons of Fox-2
have also been demonstrated as alternatively spliced in
later stages of development [15]. Between E14, postnatal
and adult mice, exon 12 inclusion increases while exons 6
and 13 are excluded. This demonstrates a complex regu-
lation of alternative splicing of this factor, with four exons
modulated between E8.5 and postnatal life.
Because some aspects of the function of Fox2 and its
binding sites within RNA sequences have been previously
characterized, we were able to predict the effect of varia-
tion of Fox2 mRNA expression on a subset of exons that
contain its putative binding sites. We compared the alter-
native splicing of cassette exons between E8.5 and E11.5
embryos as well as between E11.5 embryo and E11.5 pla-
centa (P11.5), the two stages we observed the highest dif-
ferences for Fox2  expression. The results obtained for
these ratios (Figure 7D) demonstrate that inclusion rates
of exons that are flanked by putative binding sites for
Fox2 are highly correlated with the expression of this
gene. The candidate exons were divided into two sets:
those that contained a putative Fox2 binding site within
the upstream intron, and those with a binding site in the
downstream intron. Previous studies suggest that binding
Table 3: Validation of cassette exons by RT-PCR.
Gene symbol Gene Name P-value
Itga6 Integrin α 6 5.108 e-05
Erc1 ELKS/RAB6-interacting/CAST family member 1 4.412 e-04
Kif2a Kinesin Family Member 2A 8.069 e-05
Epb4.1L3 Erythrocyte Protein Band 4.1-like 3 5.077 e-09
Numb NUMB Gene Homolog 3.463 e-07
Pml Promyelocytic Leukemia 5.884 e-06
Depdc5 DEP Domain Containing 5 9.024 e-06
Wnk1 WNK Lysine Deficient Protein Kinase 1 8.068 e-06
Mycbp2 MYC Binding Protein 2 8.881 e-06
Ganab Alpha Glucosidase 2 Alpha Neutral Subunit 5.573 e-06Revil et al. BMC Genomics 2010, 11:399
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of Fox2 upstream of the exon should result in increased
exon skipping, while downstream binding results in exon
inclusion [38]. Our results indeed demonstrate that when
the introns downstream of a cassette exon contained
UGCAUG, a hexamer representing the most specific
binding site for this protein, exon inclusion levels were
positively correlated to Fox2 expression levels, while the
opposite was true for exons with upstream binding sites.
There is nearly a ten-fold difference between the means
of exon inclusion ratios for these two categories, when
comparing E11.5 and E8.5 (P = 0.0204). We also used a
more relaxed criterion for identifying putative Fox2 bind-
ing sites, including all the binding sites previously
described [38]. This analysis increased the sample size
from 22 to 58 candidate regulated cassette exons (Addi-
tional file 4 Table S2), and resulted in increased statistical
significance levels of the regulatory effect (P = 0.0012;
Figure 7D, bars labelled "All"), suggesting that Fox2 bind-
ing sites may allow a level of degeneracy in vivo, and that
there may be a large number of splicing events regulated
by Fox2 during early embryonic development.
Discussion
Alternative splicing is frequent during early embryonic 
development
Alternative splicing is becoming a widely studied process
that can increase the transcriptome complexity using a
finite set of genes. However, little is known on the regula-
tion of alternative splicing during development, where
time and tissue specific regulation of protein levels is fun-
damental for cell differentiation, apoptosis and migration,
all key regulators of organogenesis. In this work, we show
that splicing is extensively regulated during organogene-
sis. We compile a list of 5,500 genes that indicate tran-
script isoform differences between our two tissues of
interest - embryonic and placental - or across three devel-
opmental stages, E8.5, E9.5 and E11.5. According to a 5%
FDR cutoff, we estimate that 9% of all exons are differen-
tially alternatively spliced between the placenta and the
embryo, and 2% of exons are differentially alternatively
spliced across the three developmental stages. With 5
biological replicates each, and 6 distinct tissue/stage sam-
ples, our study has considerable statistical power to
detect alternatively spliced transcripts. Our analysis also
Table 4: Validation of different alternative splicing events by real-time PCR.
Gene symbol Gene name Splicing type Microarray P-value
Elmo1 engulfment and cell motility 1, ced-12 homolog (C. elegans) altPromoter 3.536 e-09
Ank3 ankyrin 3, epithelial altPromoter 1.243 e-10
Gcnt2 glucosaminyl (N-acetyl) transferase 2, I-branching enzyme altPromoter 4.825 e-09
Tcf4 transcription factor 4 altPromoter 1.173 e-08
Kif1b kinesin family member 1B altFinish 4.562 e-10
Itsn1 intersectin 1 (SH3 domain protein 1A) altFinish 2.382e-07
Mycbp2 MYC binding protein 2 Cassette 8.881 e-06
Erc1 ELKS/RAB6-interacting/CAST family member 1 Cassette 4.412 e-06
Wnk1 WNK lysine deficient protein kinase 1 Cassette 8.068 e-06
Kif2a kinesin family member 2A Cassette 8.069e-05
Depdc5 DEP domain containing 5 Cassette 9.024e-06
Rab6 RAB6, member RAS oncogene family Mutually exclusive 2.035e-06Revil et al. BMC Genomics 2010, 11:399
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allows us to compare the fraction of genes that show iso-
form level changes with genes that are differentially
expressed at the whole transcript level. Although we find
that the number of differentially expressed genes is larger
than differentially spliced, the numbers are of similar
orders of magnitude (Figure 3). Interestingly, there is a
large overlap between these subsets, and we show that
genes with very significant levels of differential expres-
sion have a much higher than expected chance of being
alternatively spliced.
It is also worth noting that because of the high statisti-
cal power of the study, our number of differentially
expressed candidates is ten times higher than what was
previously demonstrated by a genome-wide expression
analysis of placentas and embryos at E12.5, which found
only 6.5% of statistically significant differences in gene
expression [39]. This could be explained in part by the
advances in microarray analyses - i.e. the use of whole-
transcript arrays - and the profiling of two placental
stages allowing us to target a larger number of develop-
mental events. However, it should be noted that the
observed trends in expression are highly concordant
between these two studies; most of the genes that had
been shown to be highly expressed in placentas in the
earlier study displayed the same high expression profile in
our analysis.
Although we cannot rule out that a fraction of the
genome-wide alternative splicing candidates may repre-
sent false positive results, our validation of 17 candidates
presented here, as well as the 80% success in validation of
previous experiments [40] suggests that false positives
should not significantly affect our qualitative conclusions.
It is difficult to estimate false negative rates in these types
of studies. Although they are likely to be non-negligible,
the limited power of the approach would render our esti-
mates of the true frequency of alternative splicing conser-
Figure 6 Examples of qRT-PCR validation. The results obtained from the microarray and quantitative RT-PCR follow the same trend, some of which 
are presented here. The bars (red) indicate the average of five probe set values of candidate exons divided by the average of the corresponding meta 
probe set values. The lines (blue) represent the fold change of the average of values for the qRT-PCR on the candidate exons as compared to internal 
controls on the same pre-mRNAs. Embryonic stages represented: E6.5 to E11.5; placental stages: P9.5 to P11.5.
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Table 5: Top 20 gene expression candidates in RNA binding proteins.
Gene symbol Proposed functions (GO) P-value of changes of gene 
expression
P-value of changes of 
alternative splicing
Slc6a1 Neurotransmitter transport 3.74 e-11 3.19 e-08
Dnajc6 Heat shock protein binding 2.35 e-10 1.27 e-04
Igf2bp1 mRNA stability 2.13 e-09 6.04 e-05
Enox1 Transport 6.26 e-09 1.53 e-04
Krr1 Ribosome biogenesis 6.38 e-09 N/A
Rbm13 (Mak16) Ribosome biogenesis (yeast) 6.45 e-09 N/A
Ddx39 RNA splicing, RNA helicase 6.89 e-09 1.74 e-04
Nol9 Unknown 8.02 e-09 6.76 e-05
Zfp462 Transcription regulator (during 
development)
8.98 e-09 7.13 e-04
Nup37 Transport 1.86 e-08 N/A
Rbm9 (Fox-2) RNA splicing 2.02 e-08 5.96 e-06
Pprc1 Transcription regulation 2.24 e-08 5.81 e-05
Pcbp3 Unknown 3.13 e-08 5.54 e-04
Elavl3 Cell differentiation, development 3.29 e-08 4.25 e-06
Mki67ip (Nifk) Unknown 4.05 e-08 1.57 e-06
Rbms3 Unknown 7.05 e-08 N/A
Nup43 Transport 8.34 e-08 N/A
Rbm19 rRNA processing, ribosome biogenesis 8.34 e-08 N/A
Brunol4 (Celf4) Splicing regulator 1.79 e-07 2.80 e-08
Eif3d Translation initiation 2.28 e-07 7.34 e-04Revil et al. BMC Genomics 2010, 11:399
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Figure 7 The well characterized splicing factor Fox2 is alternatively expressed and spliced during development. (a) Pre-mRNAs for this gene 
are transcribed using two primary promoters. (b) During development, the gene expression of Fox2, as detected by the meta probe set (MPS) 6836888 
increases in embryos, while remaining generally lower and stable in placentas. (c) The use of the proximal promoter increases strongly during embryo 
development. (d) Fox2 expression levels modulate the alternative splicing of cassette exons containing putative Fox2 binding sites in their surrounding 
introns. The whiskers indicate the minimum and maximum value, the box represents the 25th percentile to the 75th, the line inside the box shows the 
50th percentile and the + is the value of the mean. The strict UGCAUG binding site or a combination of 5 binding sites (All) were looked for within 100 
nt of the splicing sites in the upstream (Up) or downstream (Down) introns. The E11.5/E8.5 or E11.5/P11.5 exon inclusion ratios of the candidates were 
calculated using corresponding probe set levels, normalized by meta probe set levels. A ratio over 1 indicates that inclusion of the alternative exon 
follows expression of Fox2, while a ratio less than 1 means that these are negatively correlated. Using a one-tailed, unpaired t-test, we find that the 
means of the log of the ratios are significantly different (P < 0.05) between Up and Down data sets.
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vative. We expect that this study exposes only the tip of
the iceberg, and that a clearer picture will emerge as the
whole-genome technologies mature. In the meantime, we
provide a user-friendly database of our results in the
additional material online (Additional file 1 Table S1).
Implications for regulation of developmental pathways
In the current paradigm, regulation of developmental
pathways is accomplished mainly at the level of transcrip-
tion, and is mediated by changes in expression of certain
key genes. For example, one of the earliest events in
embryonic development is the separation of the inner cell
mass - which forms the embryo proper - from the tro-
phectoderm lineage. This event is regulated by interac-
tion between three transcription factors: Cdx2, Nanog,
and Oct4. This transcriptional regulation is essential for
turning on numerous other genes that will drive differen-
tiation of the embryo and its associated placenta. Inci-
dentally, Oct4 is known to express multiple alternatively
spliced isoforms with distinct expression patterns and
possibly distinct functions [41]. In another well-known
example, left-right asymmetry is governed by the Nodal
molecular cascade. At E7.5 Nodal  is turned on at the
node, leading to auto regulation of its own expression in
the left lateral plate, and turning on the expression of
Lefty and Pitx2 genes. These three key players form the
basis of a pathway containing numerous genes that con-
trol the specification of left versus right. Like Oct4, Pitx2,
(one of our candidates, see Additional file 1 Table S1),
expresses several isoforms with distinct transcriptional
activities [42], and only one of those isoforms, Pitx2c, is
required for left right asymmetry [43].
As the above examples demonstrate, many develop-
mental pathways include alternative isoforms of key
genes. Our own analysis presented here also indicates
that a large proportion of developmentally regulated
genes express alternative isoforms. The correct temporal
and spatial expression of those isoforms is most likely
regulated by specific splicing factors. Hence, we propose
that in addition to canonical developmental pathways
regulated by transcription factors, there exists a parallel,
and yet highly overlapping, set of pathways regulated by
splicing factors. A single splicing factor may affect the
splicing of numerous exons in a large number of genes
[18,44,45]. Thus, changes in expression levels of splicing
factors can have profound downstream effects. Moreover,
many splicing factors are themselves involved in self-reg-
ulatory feedback loops and express multiple isoforms
[46,47]. Our analysis indicates differential embryonic
expression of a number of RNA binding proteins and
putative splicing factors. One of the particularly interest-
ing examples is Fox2 (RBM9 or  Fxh), a factor whose
expression and promoter usage are both variable across
the three developmental stages (Figure 7B). We find that
Fox2 expression increases nearly 2 fold between days 8.5
and 11.5 in the embryo, but not in the placenta. We also
show that this increase in Fox2 levels has a significant and
predictable effect on the alternative splicing of cassette
exons which contain putative binding sites within 100 nt
in the neighbouring introns (Figure 7D). Furthermore,
the use of the proximal promoter, which gives rise to an
mRNA encoding a shorter N-terminus, increases
between those stages (Figure 7C). Thus, not only is the
overall amount of Fox2 product, but also the ratio of dis-
tinct isoforms, variable across early embryonic develop-
ment.
Recently Fox2 has been found to be highly expressed in
another developmentally relevant system, pluripotent cell
lines, along with other pluripotency markers such as Oct4
and Nanog. Fox2 has been shown to regulate the splicing
of numerous alternative exons in human embryonic stem
cells, and to be necessary for maintaining viability of the
cells. Moreover, Fox2 pre-mRNA contains active binding
sites for its own protein, indicating a degree of autoregu-
lation. Finally, many Fox2 targets are in turn splicing reg-
ulators, suggesting the existence of more extensive
splicing networks [38]. The properties of such networks
have been recently investigated in detail across a number
of tissues and species [48].
Future directions
Our study, along with a few recent publications [38,48-
50] demonstrates that alternative splicing is a frequent
event and is likely to have a significant role in develop-
ment. With the promising results presented here, the
future step will be to improve detection rates by using
additional developmental stages, and a finer resolution of
embryonic tissues. Indeed, the use of whole embryo
mRNAs does not permit discovery of small-scale tissue-
specific alternative splicing, which is likely to be
extremely significant to tissue differentiation. Finally,
most of our knowledge pertaining to genome-wide varia-
tion in alternative splicing has been acquired thanks to
recent developments in microarray technologies, using
either exon or splice-junction microarrays. Even more
recent advances in high throughput sequencing will soon
make it feasible to carry out whole-genome expression
and isoform profiling experiments using mRNA sequenc-
ing. This approach allows digital monitoring of expres-
sion by counting the number of reads that map to mRNA
segments of interest and comparing them across samples.
These fragments may be genes, individual exons, or spe-
cific splice junctions. mRNA sequencing also allows the
discovery of novel, as of yet unannotated, isoforms and
transcripts. Preliminary studies carried out on a limited
number of tissues and with limited sequencing coverage,
[3,4] have already significantly enlarged our catalogue of
alternatively spliced genes. With the rapidly increasingRevil et al. BMC Genomics 2010, 11:399
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throughput, along with dropping costs and accessibility
of sequencing, these technologies will soon allow us to
routinely view gene expression at the sub exon level reso-
lution and to decipher the role of splicing regulation in
development and other systems.
Conclusions
In this study, we have demonstrated that changes in alter-
native splicing are frequent during early mouse develop-
ment between tissues and stages. Indeed, the numbers of
differentially spliced genes are similar to those of differ-
entially expressed genes. In these two categories, there is
an overrepresentation of genes that have been implicated
in development. In addition, many RNA-binding proteins
are differentially spliced and/or expressed at the mRNA
level. We can see a direct correlation between expression
of Fox2, a known splicing factor, and the alternative splic-
ing of cassette exons containing binding sites for this pro-
tein in the neighbouring introns. Thus, our results
suggest that the effects of alternative mRNA isoforms
should now be systematically verified in developmental
gene studies.
Methods
Embryo collection
To generate embryos, C57BL/6J females were placed with
C57BL/6J males overnight and checked for the presence
of a vaginal plug in the morning. The day that a plug was
detected was considered embryonic day (E) 0.5. All mice
breeding and manipulations were performed in accor-
dance with the Canadian Council on Animal Research.
Embryos were collected between E6.5 - E11.5 for RNA
isolation. Embryos for RNA isolation were stored in
RNAlater (Ambion) for microarray analysis or TRIzol
(Invitrogen) for RT-PCR, and isolated according to the
manufacturers' protocol.
Microarray Hybridization
The microarray hybridization and analysis was done as
previously described [40], but using the Affymetrix
GeneChip® Mouse Exon 1.0 ST microarray. One microar-
ray was used for each of the five biological replicates used
in every stage and tissue analysed. All the microarray data
has been deposited online in NCBI's Gene Expression
Omnibus [51] with the accession number GSE21971.
http://www.ncbi.nlm.nih.gov/geo/query/
acc.cgi?acc=GSE21971.
Normalization and summarization of ExonArray 
hybridization data
The Affymetrix Mouse ExonArray contains approxi-
mately 1.2 million probe sets which target roughly 1 mil-
lion known and predicted exons. The annotations used to
design these probe sets are derived from a variety of
sources and vary dramatically in the strength of experi-
mental evidence which supports their existence. These
annotations are divided, in order of decreasing quality of
experimental support into "core", "extended", "full", "free"
and "ambiguous" annotations. Our analysis was restricted
to the approximately 2.2 × 105 core probe sets on the
ExonArray. These probe sets interrogate exons derived
from RefSeq transcripts and/or full-length GenBank
mRNAs. There are a number of issues to consider when
analysing GeneChip data from an experiment with multi-
ple arrays. These include background correction, normal-
ization, non-specific hybridization and probe
summarization. We background-corrected probe expres-
sion levels for non-specific binding based the distribution
of binding intensities of a set of "anti-genomic" probes of
a similar GC content to the probe of interest. These anti-
genomic probes are designed so as to not hybridize with
any sequence in the mouse genome and so provide an
estimate of the level of non-specific binding for a given
GC content. Probe intensities were then quantile normal-
ized across all samples. Finally, individual probe expres-
sion levels were summarized into exon- and gene-level
expression using the Probe Logarithmic Intensity Error
(PLIER) algorithm. All analyses were performed using the
Affymetrix Power Tools suite of command line programs
[52].
Data Quality Control
A major problem with inferring alternative splicing of
exons between different biological samples using
ExonArrays is differentiating such variation from changes
in whole-gene expression level. The combination of
changes in whole gene expression level with misleading
probe set results can introduce potentially artefactual sig-
nals of alternative splicing in three main ways: via (i) the
inclusion of probe sets from genes that are not expressed
in a subset of samples (ii) the inclusion of cross-hybridiz-
ing probes or (iii) the inclusion of nonresponsive or
"dead" probes [[53], Figure eight]. With these problems in
mind we employed a number of quality control protocols
to our expression data. Our objective was to minimize the
number of false positive signals of differential splicing
between our samples. Our filters are based upon the stan-
dards described by Affymetrix [53]. Firstly, in order to
differentiate genic from exonic expression changes, all
exon expression levels were normalized by the whole
gene expression level estimated by the PLIER algorithm.
Secondly, to minimize errors introduced by unexpressed
genes, we also excluded all meta-probe sets and their
constituent probe sets that were not expressed in all 25 of
our samples. A gene was defined as "not expressed" if its
mean expression level was lower than the quartile of the
distribution of all core meta probe set intensities for the
chip in question. Thirdly, we attempted to minimize theRevil et al. BMC Genomics 2010, 11:399
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influence of cross hybridizing probe sets in our analysis
by removing all probe sets in which the probe set/meta-
probe set intensity ratio was greater than 5, indicating a
high level of cross-hybridization. Finally, in order to
remove " dead" probe sets we used the detection above
b a c k g r o u n d  ( D A BG )  P - v a l u e ,  a s  e s t i m a t e d  b y  t h e  a p t -
probeset-summarize program. The DABG P-value
describes the probability that an intensity value at least as
extreme as the observed could have been drawn from the
null distribution, in this case the background distribution
of intensity values. In order to account for chip-to-chip
variation, we set a False Discovery Rate-corrected P-value
threshold at 0.05 for each chip, based on the distribution
of DABG values for that chip. In our case, a " dead" or
unresponsive probe set was defined as any probe set in
which the DABG P-value exceeded the chip-specific FDR
threshold value in all samples. In order to stabilize the
variance data values were log-transformed.
Statistical Analysis
Each probe set in our filtered dataset retained 25 esti-
mates of expression level. These estimates were divided
by tissue (embryonic and placental) and developmental
stage (days E8.5, E9.5 and E11.5 embryonic, days E9.5 and
E11.5 placental) with 5 biological replicates in each tis-
sue-stage. For simplicity, we refer to embryonic samples
as a single "tissue" throughout. The absence of placental
samples from day E8.5, due to insufficient RNA quanti-
ties, means that our dataset is unbalanced and therefore,
not amenable to analysis by standard two-way ANOVA.
Instead, we implemented the following approach. In
order to test for significant differences in expression level
between tissues we use a two-sample t-test, combining
samples from day E9.5 and day E11.5 from both tissues.
We tested for differences in expression level between
developmental stages using a two sample t-test in pla-
centa to compare expression level on day E9.5 and day
E11.5, and using a one-way ANOVA in embryo to com-
pare expression levels on days E8.5, E9.5 and E11.5. The
p-values for these latter two tests were then combined
using Fisher's method [54] under the common null
hypothesis of no significant variation in expression level
across developmental stages in either tissue. All p-values
were adjusted for multiple testing by using the Benjamini
and Hochberg [55] FDR procedure, and a false discovery
rate of 0.05 was used as a cutoff for reporting the results.
Fox2 effect on alternative cassette exon inclusion
In order to confidently identify cassette exons, of the top
2830 significant probe sets (Additional file 1 Table S1), we
selected those that were annotated as "cassetteExon" in
the "knownAlt" track on the UCSC Genome Browser
[30]. As binding sites for Fox2 are found predominantly in
the surrounding introns within 100 nt of the splicing sites
[38], upstream and downstream introns were scanned for
the presence of several different putative binding sites
previously published [38], using sequences extracted with
the UCSC Table Browser data retrieval tool [56]. We then
calculated E11.5/E8.5 and E11.5/P11.5 ratios for each
probe set value, normalized to the corresponding meta
probe set. This ratio corresponds to the predicted ratio of
exon inclusion levels. The candidate exons were divided
into two sets: those that contained a putative Fox2 bind-
ing site within the upstream intron, and those with a
binding site in the downstream intron. The data was log-
transformed in order to stabilize the variance of the
ratios, and the differences between the two sets were
analysed using a one-tailed, unpaired Welch's t test [57].
The results were considered significant if the p-values for
the difference between the means were less than 0.05 (P <
0.05).
End-point PCR validation
Standard PCR validation was done using HotStarTaq
PCR mix (Qiagen) according to the manufacturer's
instructions. 8 ng of cDNA were used in a 10 μl reaction
with conditions set as follows: 15 minutes at 95°C, fol-
lowed by 30 cycles of 30 seconds at 95°C, 30 seconds at
58°C and 45 seconds at 72°C. The resulting products were
analyzed on a 2% agarose gel (Additional file 3 Figure S2).
Primer sequences used are available in additional table
(Additional file 4 Table S3).
Real-time PCR validation
The validation of the results by qPCR was done in a 384-
well format using the 7900HT Fast Real-Time PCR Sys-
tem (Applied Biosystems) and the Power SYBR® Green
PCR Master Mix (Applied Biosystems) according to the
manufacturer's protocol. The concentrations of the
reagents used were 8 ng of cDNA was in a 10 μl reaction
with 320 nM of each primer. The parameters of the qRT-
PCR machine were 10 minutes at 95°C, followed by 40
cycles of 20 seconds at 95°C, 30 seconds at 58°C and 45
seconds at 72°C. The primers used are shown in addi-
tional table (Additional file 4 Table S4).
Additional material
Additional file 1 Figure S1 - Data filtering. Fold-change in percentage 
overlap of predicted alternatively-spliced exons in our analysis with alterna-
tively spliced events based on UCSC "known" genes versus False Discovery 
Rate (FDR) P-value threshold.
Additional file 2 Table S1 - Candidates. A list of all significant alterna-
tively spliced candidates found during our analysis.
Additional file 3 Figure S2 - PCR validation. Results of the endpoint PCR 
validation of alternative cassette exons.
Additional file 4 Additional tables . Table S2 Table containing primers 
used for end-point PCR validation. Table S3 Table containing primers used 
for qRT-PCR validation. Table S4 Information about binding sites found for 
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